[go: up one dir, main page]

AR054595A1 - Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis - Google Patents

Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis

Info

Publication number
AR054595A1
AR054595A1 ARP060103292A ARP060103292A AR054595A1 AR 054595 A1 AR054595 A1 AR 054595A1 AR P060103292 A ARP060103292 A AR P060103292A AR P060103292 A ARP060103292 A AR P060103292A AR 054595 A1 AR054595 A1 AR 054595A1
Authority
AR
Argentina
Prior art keywords
guanfacine
single dose
pharmaceutical formulations
daily administration
administration form
Prior art date
Application number
ARP060103292A
Other languages
English (en)
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37668083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054595(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Llc filed Critical Shire Llc
Publication of AR054595A1 publication Critical patent/AR054595A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulaciones terapéuticas de guanfacina en forma de una unica dosis una vez al día que tienen tamano total de tableta util.
ARP060103292A 2005-07-28 2006-07-28 Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis AR054595A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70298205P 2005-07-28 2005-07-28

Publications (1)

Publication Number Publication Date
AR054595A1 true AR054595A1 (es) 2007-06-27

Family

ID=37668083

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103292A AR054595A1 (es) 2005-07-28 2006-07-28 Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis

Country Status (18)

Country Link
US (1) US20070048371A1 (es)
EP (1) EP1909766B1 (es)
JP (2) JP5726401B2 (es)
KR (1) KR20080041669A (es)
CN (1) CN101252917A (es)
AR (1) AR054595A1 (es)
AU (1) AU2006275718B8 (es)
BR (1) BRPI0615989B8 (es)
CA (1) CA2616181C (es)
DK (1) DK1909766T3 (es)
ES (1) ES2566395T3 (es)
IL (1) IL188980A0 (es)
NO (1) NO20081038L (es)
NZ (1) NZ565649A (es)
RU (1) RU2435573C2 (es)
TW (1) TW200744672A (es)
WO (1) WO2007016284A2 (es)
ZA (1) ZA200801575B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0916163D0 (en) * 2009-09-15 2009-10-28 Shire Llc Prodrugs of guanfacine
HUE044221T2 (hu) * 2010-02-03 2019-10-28 Pharma Two B Ltd Nyújtott hatóanyagleadású razagilin készítmények és alkalmazásaik
WO2011156710A2 (en) * 2010-06-11 2011-12-15 Shire Llc Combination therapy with lisdexamphetamine and extended release guanfacine
US20120041068A1 (en) * 2010-08-11 2012-02-16 Aptapharma, Inc. Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility
CN102525983A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 胍法新缓释片及其制备方法
CN102579381B (zh) * 2012-03-30 2013-07-10 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
WO2014159340A1 (en) 2013-03-13 2014-10-02 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
US9180104B2 (en) 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
US10022341B2 (en) 2014-12-02 2018-07-17 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
CN108289848A (zh) * 2015-12-08 2018-07-17 阿迪亚生命科学公司 包含urat1的有效抑制剂的药物组合物
JP6656670B2 (ja) * 2016-03-11 2020-03-04 国立大学法人 鹿児島大学 抗ｈｃｖ活性を有する薬剤
EP4085907A1 (en) * 2016-04-20 2022-11-09 New Frontier Labs, LLC Diethyl azelate in the treatment of type 2 diabetes
WO2019136224A1 (en) * 2018-01-05 2019-07-11 Shire Human Genetic Therapies, Inc. Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders
JP2023035359A (ja) * 2021-09-01 2023-03-13 東和薬品株式会社 グアンファシン製剤
EP4292587A1 (en) 2022-06-15 2023-12-20 Sawai Pharmaceutical Co., Ltd. Guanfacine hydrochloride containing pharmaceutical preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649918A5 (de) * 1981-07-09 1985-06-28 Sandoz Ag Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie.
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
DE19834573A1 (de) * 1998-07-31 2000-02-03 Bayer Ag Doppelmetallcyanid-Katalysatoren für die Herstellung von Polyetherpolyolen
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US6635277B2 (en) * 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SI1355633T1 (en) * 2001-12-19 2005-06-30 Astrazeneca Ab NEW FILM COATING containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
CA2481236A1 (en) * 2002-03-29 2003-10-09 Alza Corporation Volume efficient controlled release dosage form
US6763509B2 (en) * 2002-09-26 2004-07-13 Sun Microsystems, Inc. Method and apparatus for allocating decoupling capacitor cells
US20070104782A1 (en) * 2005-07-28 2007-05-10 Ibrahim Melissa E Modified release tablet formulations with enhanced mechanical properties

Also Published As

Publication number Publication date
ES2566395T3 (es) 2016-04-12
NZ565649A (en) 2011-03-31
BRPI0615989A2 (pt) 2011-05-31
JP5726401B2 (ja) 2015-06-03
CA2616181A1 (en) 2007-02-08
BRPI0615989B1 (pt) 2020-05-26
JP2009502951A (ja) 2009-01-29
RU2435573C2 (ru) 2011-12-10
WO2007016284A3 (en) 2007-03-29
US20070048371A1 (en) 2007-03-01
IL188980A0 (en) 2008-08-07
AU2006275718A1 (en) 2007-02-08
AU2006275718A8 (en) 2012-11-01
BRPI0615989B8 (pt) 2021-05-25
CA2616181C (en) 2015-02-17
KR20080041669A (ko) 2008-05-13
NO20081038L (no) 2008-04-23
EP1909766B1 (en) 2016-03-16
DK1909766T3 (en) 2016-04-04
AU2006275718B8 (en) 2012-11-01
WO2007016284A2 (en) 2007-02-08
AU2006275718B2 (en) 2012-10-04
TW200744672A (en) 2007-12-16
EP1909766A2 (en) 2008-04-16
CN101252917A (zh) 2008-08-27
JP2012229253A (ja) 2012-11-22
RU2008102911A (ru) 2009-09-10
ZA200801575B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
AR054595A1 (es) Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
BR112012008317A2 (pt) produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
ECSP066534A (es) Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia
PT2269631E (pt) Composições farmacêuticas compreendendo neurotoxina botulínica para utilização em medicina e cosmética
CO6400186A2 (es) Tabletas de acetato de ulipristal
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
EA201170512A1 (ru) Композиция для перорального введения
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
NO20082097L (no) Farmasoytiske sammensetninger
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
CY1114933T1 (el) Στερεες φαρμακευτικες συνθεσεις σταθερης δοσης περιεχουσες ιρβεσαρτανη και αμλοδιπινη, η παρασκευη τους και η θεραπευτικη εφαρμογη τους
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
BRPI0508596A (pt) combinação compreendendo ligante alfa-2-delta
TR200806300A2 (tr) Çözünürlük artırıcı farmasötlk formulasyon
CL2008000227A1 (es) Composicion farmaceutica que comprende una combinacion de uso oral de tramadol y ketoprofeno; y uso en el tratamiento del dolor.
ES2325291A1 (es) "uso de un extracto de silybum marianum"
CO6351711A2 (es) Combinacion de dosis fija en la forma de una tableta de dos copas o de una sola capa de alisquireno y amlodipina
PA8802001A1 (es) Combinación antiretroviral novedosa
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
EA201290378A1 (ru) Композиции, содержащие нестероидные противовоспалительные лекарственные средства
AR067351A1 (es) Combinacion de picotamida con nafronil
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
CL2007002762A1 (es) Composicion farmaceutica que comprende orlistat 60mg y rosuvastatina calcica equivalente a 5mg de rosuvastatina en una sola unidad de dosis, util para el tratamiento de la obesidad y la dislipidemia.

Legal Events

Date Code Title Description
FB Suspension of granting procedure